Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug

An amino and alkyl technology, applied in the field of preparing tubulin inhibitors, can solve the problems of inconvenient use

Active Publication Date: 2013-04-03
ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still ma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug
  • Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug
  • Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] (Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methylpiperidine-4-formyl)amino-4-ethoxyphenyl)ethylene synthesis

[0070]

[0071] Step 1: Synthesis of Trimethoxybenzyltriphenylphosphine Bromide

[0072] Dissolve 4Kg of 3,4,5-trimethoxybenzaldehyde in absolute ethanol, stir, and add 1.4Kg of sodium borohydride in small amounts at a temperature below 35°C. After the addition was complete, the reaction was carried out overnight. After the reaction was complete, ethanol was removed by rotary evaporation. Ethyl acetate (10L×4) was added for extraction, the ethyl acetate layers were combined, dried over anhydrous magnesium sulfate, filtered, and the ethyl acetate was distilled off under reduced pressure to obtain 3200ml of the product.

[0073] Dissolve 3200ml of 3,4,5-trimethoxybenzyl alcohol in 20L of toluene, stir, cool down to -5-0°C, add 1L of phosphorus tribromide dropwise, and control the temperature at -5-0°C. After the dropwise addition was completed, react at low te...

Embodiment 2

[0083] (Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methylpiperidine-4-formyl)amino-4-ethoxyphenyl)ethylene lemon Salt preparation

[0084] (Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methylpiperidine-4-formyl)amino-4-ethoxyphenyl)ethylene Add 20g into 200ml of acetone, heat to dissolve, add 10g of citric acid, continue to heat and reflux for 3h, filter the precipitate after cooling, and recrystallize with ethanol to obtain the compound shown in the title.

[0085] Utilize different raw materials, by the similar method of embodiment 1, synthesized following various compounds respectively:

[0086]

[0087]

[0088]

[0089]

[0090]

[0091]

Embodiment 31

[0092] Example 31 Pharmaceutical preparation formulation

[0093] The invention provides formulations of pharmaceutical compositions for several diseases related to abnormal proliferation of new blood vessels, and the pharmaceutical compositions mainly include oral preparations such as tablets and capsules. Hereinafter, the compounds shown in the present invention are represented by "active compound".

[0094]

[0095]

[0096]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a compound which is shown as a formula (I) and used for inhibiting generation of tumour neovascularization as well as officinal salt or a configurational isomer thereof, wherein substituent groups R1, R2 and R3 are defined in the specification. The invention also discloses a preparation method of the compound in the formula (I), a pharmaceutical composition and an application of the compound as a microtubulin inhibitor in the aspect of inhibiting the tumour neovascularization, especially an application as an oral preparation.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a series of Combretastatin A4 derivatives, a preparation method thereof, and an application in preparation of tubulin inhibitors. Background technique [0002] Combretastatins series compounds were originally extracted and isolated from the trunk of Combretum caffrum in South Africa. It has anti-tumor activity, can directly act on endothelial cells, induce the apoptosis of proliferating endothelial cells, thereby inhibiting the formation of neovascularization in tumors, and achieve the purpose of eradicating tumors. Combretastatins series compounds have a cis-1,2-stilbene structure. Among them, combretastatin A-4[CA-4, Comprestatin, cis-1-(3,4,5-trimethoxy)phenyl-2-(3′-hydroxy-4′-methoxy)benzene Vinyl] has the strongest inhibition of microtubule polymerization (Pettit G R, et al. J. Med. Chem (1995) 38 1666-1672). Recently, as a tumor vessel targeting agent, CA-4 has shown exce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D211/62C07D401/04C07D409/04C07D213/82C07D213/81C07D213/84A61K31/4468A61K31/4545A61K31/454A61K31/4535A61K31/455A61K31/44A61P35/00A61P35/02A61P29/00A61P19/02A61P27/02A61P17/06A61P37/00A61P27/06A61P31/04A61P31/10A61P31/22A61P33/02A61P1/02A61P31/18A61P15/00
CPCC07D213/84A61K31/4535C07D213/81C07D409/04A61K31/454A61K31/4545A61K31/455A61K31/4468C07D211/62C07D401/04C07D213/82A61P1/02A61P15/00A61P17/06A61P19/02A61P27/02A61P27/06A61P29/00A61P31/04A61P31/10A61P31/18A61P31/22A61P33/02A61P35/00A61P35/02A61P37/00
Inventor 王建平王建国
Owner ZHEJIANG DADE PHARMACEUTICAL GROUP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap